


609



MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO-1449				Docket Number (Optional) 3153.00451		Application Number 10/673,008	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Applicant Deng, et al.			
				Filing Date 09/26/2003		Group Art Unit 1636	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>EL</i>	6,713,286	03-2004	Deng, et al.	435	91.33		
<i>JP</i>	6,764,676	07-2004	Deng, et al.	424	93.21		
<i>JZ</i>	2004/0096460	05-2004	Deng, et al.	424	199.1		
FOREIGN PATENT DOCUMENTS							
	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)							
EXAMINER <i>David Lugo</i>				DATE CONSIDERED 1/4/06			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) 3153.00451	Application Number 10/673,008
	Applicant Deng, et al.	
	Filing Date 09/26/2003	Group Art Unit 1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PC	5,177,014	01-1993	O'Connor et al.	435	188	
* OZ	5,833,883	11-1998	Wardley et al.	424	208.1	
* OZ	6,004,799	12-1999	Luciw et al.	435	236	
* OZ	6,300,118 B1	10-2001	Chavez et al.	435	252.3	
* OZ	6,348,196 B1	02-2002	Audonnet et al.	424	202.1	
OZ	6,383,765	05-2002	Andersen et al.	435	7.92	

FOREIGN PATENT DOCUMENTS

	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
* OZ	WO 9530019	11-1995	PCT				
* OZ	WO 9640268	12-1996	PCT				
* OZ	WO 9732983	09-1997	PCT				
* OZ	WO 9803660	01-1998	PCT				
* OZ	WO 9821354	05-1998	PCT				
* OZ	WO 9840493	09-1998	PCT				
* OZ	WO 9840957	09-1998	PCT				
* OZ	0997529A2	08-1999	EP				
* OZ	2751223A1	07-1996	FR				

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

* OZ	Andresson et al., Nucleotide sequence and biological properties of a pathogenic proviral molecular clone of neurovirulent visna virus. Virol. 1993, Vol. 193, pages 89-105. See entire document.
* OZ	Baldinotti, et al., J. Virol., Vol. 68:4572-5479 (1994)
* OZ	Baumberger, et al., AIDS, 7:S59-S64 (1993)
* OZ	Bishop, et al., Vaccine, Vol. 14:1243-1250 (1996)
* OZ	Boyer, et al., Protection of Chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination, Nature Medicine, Vol 3, Numbers 5, Pages 526-532, May 1997.
* OZ	Cox et al. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virol. 1993, Vol. 195, pages

	845-850. See entire document.				
• <i>82</i>	Cuisinier, et al., Vaccine. Vol. 15:1085-1094 (1997)				
• <i>82</i>	Cuisinier, et al., Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection, Vaccine 17, p 415-425, Elsevier Science Ltd. (1999)				
• <i>81</i>	Diehl, et al., J. Virol., Vol. 69:2328-2332 (1995)				
• <i>82</i>	Diehl, et al., J. Virol., Vol. 70:2503-2507 (1996)				
• <i>82</i>	Elyar, et al., Vaccine, Vol. 15:1537-1444 (1997)				
• <i>81</i>	Franchini et al. Highly attenuated HIV type 2 recombinational poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macques. AIDS Res. Human Retro. 1995, Vol. 11, No. 8, Pages 909-920. See entire document.				
• <i>81</i>	Gonda et al. Bovine immunodeficiency virus: molecular biology and virus-host interactions. Virus Res. 1994, Vol. 32, pages 155-181. See entire document.				
• <i>81</i>	Hoesie, et al., DNA Vaccination Affords Significant Protection against Feline Immunodeficiency Virus Infection without inducing Detectable Antiviral Antibodies, Journal of Virology, Vo. 72, No. 9, p. 7310-7319, Sept. 1998				
• <i>81</i>	Okuda et al. Induction of potent humoral and cell-mediated immune response following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res. Human Retro. 1995, Vol. 11, No. 8, pages 933-943. See entire document.				
• <i>81</i>	Olmsted, et al., Molecular cloning of feline immunodeficiency virus. Proc. Natl. Acad. Sci. USA. April 1989, Vol. 86, pages 2448-2452. See entire document.				
• <i>81</i>	Pincus et al. Poxvirus-based vectors as vaccine candidates. Biologicals. 1995, Vol. 23, pages 159-164. See entire document.				
• <i>81</i>	Saltarelli et al. Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus. Virol. 1990, Vol. 179, pages 347-364. See entire document.				
• <i>81</i>	Von Schwedler, et al., Retroviral-Mediated Expression of FIV Envelope/Rev Induces CD8+ CTL Response in Mice, Intervirology 1997; 40:271-276.				
• <i>81</i>	Wardley et al. The use of feline herpesvirus and baculovirus as vaccine vectors for the gag and env genes of feline leukaemia virus. J. Gen. Virol. 1992, Vol. 73, pages 1811-1818. See entire document.				
• <i>82</i>	Whetter, et al., Equine infectious anemia virus derived from a molecular clone persistently infects horses. J. Virol. December 1990, Vol. 64, No. 12, pages 5750-5756. See entire document.				
<table border="1" style="width: 100%;"> <tr> <td style="width: 50%;">EXAMINER</td> <td style="width: 50%;">DATE CONSIDERED</td> </tr> <tr> <td><i>David Lugo</i></td> <td><i>1/4/06</i></td> </tr> </table>		EXAMINER	DATE CONSIDERED	<i>David Lugo</i>	<i>1/4/06</i>
EXAMINER	DATE CONSIDERED				
<i>David Lugo</i>	<i>1/4/06</i>				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.					

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

*Copies of all of the references cited herein were previously provided and considered by the Examiner during the prosecution of the parent application, now U.S. Patent No. 6,667,298.